Study on the possibility of insulin as a carrier of IUdR for hepatocellular carcinoma-targeted therapy

Table 1 Values of Bmax and Kd of ¹²⁵I-insulin binding to insu-lin receptor in hepatocellular carcinoma and its adjacent liver tissue (mean ± SD for six identical experiments)

	High affinity sites		Low affinity sites
	Bmax (nmol·L-1)	Kd (nmol·L-1)	Bmax (nmol·L-1)	Kd (nmol·L-1)
Hepatocellular carcinoma	1.58 ± 0.16a	2.20 ± 0.66	0.36 ± 0.11	18.80 ± 7.85
Adjacent liver tissue	1.09 ± 0.51	2.21 ± 0.72	0.33 ± 0.74	17.89 ± 7.87

^aP < 0.05 vs adjacent liver tissue. Bmax was the maximal amount of ligand bound; Kd was the dissociation constant of the bind-ing site for the ligand.

Table 2 Values of IC₅₀ and KI for insulin-IUdR and insulin competing with ¹²⁵I-insulin for binding to insulin receptor on hepatocellular carcinoma (mean ± SD for four identical experiments)

	High affinity sites		Low affinity sites
	IC50 (nmol·L-1)	KI (nmol·L-1)	IC50 (nmol·L-1)	KI (nmol·L-1)
Insulin-IUdR	11.50 ± 2.83b	11.26 ± 2.65b	19.35 ± 5.11	19.30 ± 5.02
Insulin	5.01 ± 1.24	4.85 ± 1.12	17.75 ± 4.86	17.69 ± 4.81

^bP < 0.01 vs insulin. IC₅₀ was the concentration of competing ligand to displace radioligand binding by 50%; KI was the dissociation constant of competing ligand.